Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
Quick Facts
What This Study Found
In Study A, bremelanotide subjects lost an average of 1.3 kg more than placebo; in Study B, those on twice-daily bremelanotide lost 1.7 kg compared to 0.9 kg for placebo.
Key Numbers
How They Did This
Two phase 1 randomized controlled trials were conducted, one with a 1:1 placebo comparison and another as a crossover trial with multiple treatment sequences.
Why This Research Matters
These results indicate that bremelanotide could be a promising treatment for obesity, potentially aiding in weight management for women. Understanding its effects on appetite regulation may lead to better obesity interventions.
What This Study Doesn't Tell Us
The study had a small sample size and was limited to premenopausal women, which may affect the generalizability of the results.
Trust & Context
- Original Title:
- Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
- Published In:
- Diabetes, obesity & metabolism, 24(6), 1084-1093 (2022)
- Authors:
- Spana, Carl(2), Jordan, Robert(2), Fischkoff, Steven
- Database ID:
- RPEP-06512
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06512APA
Spana, Carl; Jordan, Robert; Fischkoff, Steven. (2022). Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.. Diabetes, obesity & metabolism, 24(6), 1084-1093. https://doi.org/10.1111/dom.14672
MLA
Spana, Carl, et al. "Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.." Diabetes, 2022. https://doi.org/10.1111/dom.14672
RethinkPeptides
RethinkPeptides Research Database. "Effect of bremelanotide on body weight of obese women: Data ..." RPEP-06512. Retrieved from https://rethinkpeptides.com/research/spana-2022-effect-of-bremelanotide-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.